Cariprazine side effects: akathisia, insomnia, the long half-life

Cariprazine, marketed as Vraylar, is the third partial dopamine agonist to reach the US market, after aripiprazole and brexpiprazole. It shares much of their conceptual logic — partial activation of D2 receptors, with the goal of stabilising rather than blocking dopamine signalling — but with two distinctive features. First, it preferentially binds the D3 receptor, which has been theorised to help with negative symptoms and depression. Second, and more practically important, it has the longest half-life of any oral antipsychotic on the market. The active metabolite hangs around for weeks. That single fact shapes most of what is unique about the side effect experience.

The half-life and why it matters

Cariprazine itself has a half-life of around two days, but its active metabolite, didesmethyl-cariprazine, has a half-life of about three weeks. That is unusual. Most antipsychotics reach steady state in days; cariprazine takes weeks. The implications for patients:

• A dose increase will not feel "fully on" for two to four weeks
• Side effects from a dose increase may also continue to emerge over that period
• Stopping cariprazine does not mean it is out of your system — it tapers itself for weeks
• Missing a dose for a day or two has less effect than with shorter-acting drugs

This pattern requires patience from both patients and prescribers. Reflexive dose adjustments based on early side effects can lead to over-correction.

Akathisia

Akathisia is the most common reason patients struggle with cariprazine. Rates in pivotal trials were 10–20%, depending on dose. The pattern is similar to aripiprazole — restlessness, an urge to move, sometimes pacing. The long half-life can make it harder to assess whether akathisia is settling or escalating, because the drug effect is still building weeks into treatment.

Strategies:

• Lower the dose if clinically possible — the half-life means patience is required
• Add a beta-blocker (often propranolol)
• Short-term benzodiazepine support
• Switch if persistent

Insomnia

Cariprazine is more activating than sedating, similar to aripiprazole. Insomnia rates in trials are around 8–10%. Most prescribers favour morning dosing for this reason. Standard sleep hygiene measures and, occasionally, short-term sleep aids help during the early weeks.

Weight and metabolic effects

Cariprazine produces modest weight gain — generally less than olanzapine or quetiapine, comparable to or slightly more than aripiprazole. Average gains in trials are typically 1–3 kg over the first year. Effects on lipids and glucose are modest. Standard metabolic monitoring applies.

Impulse-control concerns

Like the other partial agonists, cariprazine carries the FDA class warning for pathological gambling, hypersexuality, compulsive shopping, and binge eating. The cases described in the literature largely mirror those reported with aripiprazole. Patients and families should be told what to look for.

Movement effects

Beyond akathisia, cariprazine can cause parkinsonism (tremor, stiffness, slowed movement), particularly at higher doses. Tardive dyskinesia is a long-term concern as with all dopamine-acting antipsychotics, though rates appear to be on the lower end. Periodic AIMS screening is standard.

Prolactin

Cariprazine, like aripiprazole and brexpiprazole, tends to be prolactin-neutral or prolactin-lowering. This makes it a reasonable option for patients who developed symptomatic hyperprolactinemia on risperidone or paliperidone.

Other reported effects

• Nausea — common in the first weeks
• Constipation — modest, manageable with hydration and fibre
• Headache — particularly during titration
• Dizziness and orthostatic hypotension — modest
• Anxiety and activation — sometimes described as feeling "wired"

Approved uses

• Schizophrenia in adults
• Acute manic and mixed episodes of bipolar I disorder
• Bipolar I depression
• Adjunctive treatment of major depressive disorder (added in 2022)

Boxed warnings

Like all antipsychotics:

• Increased mortality in elderly patients with dementia-related psychosis
• Increased risk of suicidality in young adults treated for depression

When to call the prescriber

• Persistent restlessness, especially worsening over time
• New compulsive urges
• New tremor, stiffness, or involuntary movements
• Significant insomnia
• Pregnancy planning — cariprazine's long half-life has implications for any planned conception

The pregnancy question

Because didesmethyl-cariprazine persists for weeks, even stopping the drug well before conception does not eliminate fetal exposure quickly. This is worth discussing with a prescriber for any patient of childbearing potential who is considering pregnancy. The National Pregnancy Registry for Atypical Antipsychotics (run by Massachusetts General Hospital) collects ongoing data.

Switching considerations

If cariprazine is not the right fit, common alternatives include:

• Aripiprazole — shorter half-life, easier to titrate up or down
• Brexpiprazole — partial agonist with less akathisia/insomnia
• Lurasidone — different mechanism, food-dependent
• Lumateperone — newer, very metabolically light, simple dosing

The takeaway

Cariprazine is an option for patients who need a partial-agonist mechanism, particularly those with prominent depressive symptoms or who haven't tolerated the alternatives. Its long half-life is a feature for some — fewer rebound effects from missed doses — and a challenge for others, particularly during dose-finding. Honest conversation with the prescriber about the kinetics, and patience during titration, are the keys to a productive trial.

This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.